Wockhardt has entered into a strategic global alliance with Sheffield Bio-Science, a Kerry Group Business from the USA. Under this partnership, Sheffield Bio-Sciences will have exclusive sales and distribution rights to supply recombinant insulin to the cell culture markets worldwide. According to estimates, the potential in cell culture markets is around US$ 50 million. As a part of the alliance over a period of time, Wockhardt shall develop and supply Animal Component Free (ACF) recombinant insulin for the distribution in the cell culture markets.
Dr Habil Khorakiwala, chairman of Wockahrdt, said, “This partnership is a reaffirmation of Wockhardt's biotechnology research prowess and a confluence of innovative novel technology now being offered to global cell culture markets.”
Sheffield's director of Global Business Development, Hans Huttinga stated, “We are looking forward to developing a strong and lasting partnership between our organizations.”
Wockhardt was the first in Asia and only the fourth company in the world to have developed, manufactured and marketed Wosulin – recombinant insulin injectables.
“This strategic alliance marks another step in our continued investment to strengthen our cell culture media supplement portfolio.” said Edmond Scanlon, president of Sheffield Bio-Science.